Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre

Sotiriou, Elena; Tsentemeidou, Aikaterini; Bakirtzi, K; Lallas, Aimilios; Ioannides, Dimitrios; Vakirlis, Efstratios

doi:10.1111/jdv.17582

Cited by 67 publications

(95 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two middle-aged women developed a rosacea-like eruption 4 to 5 days after Ad26.CoV2.S and BNT162b2 vaccination [57]. In some patients, COVID vaccination may induce a new onset of psoriatic disease, presenting as chronic plaque psoriasis [58,59], palmoplantar psoriasis [60], guttate psoriasis [61], generalized pustular psoriasis [62], and even pityriasis rubra pilaris [63].…”

Section: Other Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

Section: Other Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Notably, there was no difference between the types of the vaccine (50% mRNA technology vaccines and 50% adenovirus vaccine) used. Similarly, PASI was not statistically different in different vaccine groups (P = 0.073, 95% confidence interval -0.36 to 6.96) [53].…”

Section: Covid-19 Vaccines and Exacerbation Of Psoriasismentioning

confidence: 80%

“…Wide range of cutaneous side effects are being reported with different types of SARS-CoV-2 vaccines including early-onset or delayed-type local injection reactions, maculopapular rash, erythema multiforme, pernio and urticaria. [48] Exacerbation of chronic inflammatory skin disorders such as psoriasis has also been recently described [49][50][51][52][53].…”

Section: Covid-19 Vaccines and Exacerbation Of Psoriasismentioning

confidence: 99%

“…Of these, nine patients had had known mild psoriasis, which had been left without treatment for over a year. Five patients had only been receiving topical treatment (steroids, calcipotriol/betamethasone), with which they adequately controlled their disease [53]. Psoriasis flare was treated with topical calcipotriol/betamethasone (five cases) and systemic agents or phototherapy (nine cases).…”

Section: Covid-19 Vaccines and Exacerbation Of Psoriasismentioning

confidence: 99%

“…In our opinion, these recommendations should be extended to all patients with psoriasis, both those receiving treatment and those not currently being treated. Finally, possible exacerbations of psoriasis in patients undergoing treatment should not, in our opinion, be a reason to renounce vaccination, also because the cases that have occurred and are reported in the literature have all resolved without complications[49][50][51][52][53].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy

Diotallevi

Campanati

Radi

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

More than 12 months have passed since the World Health Organization (WHO) declared Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on 11 March 2020. The entire world scientific community agrees that at this time vaccine is the most promising weapon to combat the infection and the severity of the disease. According to the document “Draft landscape of COVID-19 candidate vaccines” by WHO, 272 vaccines against SARS-CoV-2 virus are in development, although only four of these, produced by Pfizer-BioNTech (Pfizer, Inc. and BioNTech), Moderna, AstraZeneca, and Janssen companies, respectively, have been approved by European Medicines Agency and Italian Medicines Agency and subsequently distributed nationwide for use. These vaccines are the result of highly innovative procedures and are quite different from each other in terms of composition. Even clinicians in various medical fields may be unfamiliar with the effects of these vaccines. There is the strong emerging need for dermatologists to understand the crucial role of vaccines, with a focus on the need to vaccinate patients suffering from immune-mediated skin diseases, such as psoriasis, while taking the ongoing treatment into consideration regarding the timing of vaccination. Similarly, psoriasis patients aware of having an immune-mediated and inflammatory disease are increasingly asking the dermatologist information about the efficacy and safety of vaccines against SARS-CoV-2 virus. In this narrative review of the literature and critical analysis of the recommendations of the Italian Ministry of Health, we analyze the implications of the vaccination campaign on dermatological patients with psoriasis undergoing immunosuppressive treatment.

show abstract

A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine

Sun

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission. There is currently a lack of real‐world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID‐19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor‐α (TNF‐α) and interleukin‐17A (IL‐17A) inhibitors. Methods We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID‐19 vaccine (either BBIBP‐CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF‐ α inhibitors or IL‐17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy. Results After inactivated COVID‐19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment (p < 0.05 and p < 0.01, respectively). Routine blood tests and hepatorenal function analyses suggested that inactivated SARS‐CoV‐2 vaccines did not alter the safety of biologics treatment (p > 0.05). Conclusions Inactivated SARS‐CoV‐2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF‐α inhibitors or IL‐17A inhibitors) in patients with moderate to severe plaque psoriasis.

show abstract

Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre

Cited by 67 publications

References 6 publications

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy

A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine

Contact Info

Product

Resources

About